We demonstrated that up to eight infusions of 10 × 109 EGFR BATs were feasible, safe, and well tolerated in both every 4-week and weekly regimens while inducing cellular and cytokine/chemokine anti-glioma immune responses. The gene discussed is EGFR; the disease is central nervous system cancer.